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Abstract
Next-generation sequencing (NGS) is replacing other molecular techniques to become the de facto gene diagnostics
approach, transforming the speed of diagnosis for patients and expanding opportunities for precision medicine.
Consequently, for accredited laboratories as well as those seeking accreditation, both objective measures of quality and
external review of laboratory processes are required. External quality assessment (EQA), or Proficiency Testing (PT), can
assess a laboratory’s service through an independent external agency, the EQA provider. The analysis of a growing number
of genes and whole exome and genomes is now routine; therefore, an EQA must be delivered to enable all testing
laboratories to participate. In this paper, we describe the development of a unique platform and gene target independent EQA
scheme for NGS, designed to scale from current to future requirements of clinical diagnostic laboratories testing for germline
and somatic variants. The EQA results from three annual rounds indicate that clinical diagnostic laboratories are providing
an increasingly high-quality NGS service and variant calling abilities are improving. From an EQA provider perspective,
challenges remain regarding delivery and performance criteria, as well as in analysing similar NGS approaches between
cohorts with meaningful metrics, sample sourcing and data formats.
Introduction
The decrease in cost and wide availability of next-
generation sequencing (NGS) has enabled the application
of this technique in numerous aspects of routine clinical
medical diagnostics and NGS is therefore replacing other
molecular techniques to become the de facto standard,
transforming the speed of diagnosis for patients and
expanding opportunities for precision medicine [1–3].
Whatever NGS approach is deployed, clinical diagnostic
laboratories must provide the correct test result, accurately
interpreted, to the right patient within an appropriate time-
frame. Any errors in this process may result in inappropriate
clinical decisions for patient management, treatment, and in
the case of inherited disease, could have an impact beyond
the patient’s own diagnosis.
NGS also presents challenges when implemented into
routine clinical diagnostic practice not only in terms of cost
implications of validation, but also knowledge and capacity
for data analysis. Consequently, more efficient and struc-
tured sharing of validation and quality control data, as well
as variant annotation and analytical strategies could help
minimise wasteful duplication and speed progress in iden-
tifying new genomics-based tests, helping to translate them
into the clinic [4]. This creates the need for multiple skill
sets and reconfiguration of current diagnostic processes.
Best practice guidelines (BPG) for NGS-based tests set
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comprehensive requirements on a laboratory’s own Internal
Quality Control (IQC) practices not only for the sequencing
but also quite extensively for the complex bioinformatics
workflows [5–8]. For accredited laboratories, and those
seeking accreditation, objective measures of quality such as
external review of laboratory processes are critical.
Medical laboratory accreditation to a recognised stan-
dard, for example ISO 15189 [9], is one such system of
external review. ISO 15189 accreditation requires that
laboratories regularly participate in EQA for all tests per-
formed. The objectives of EQA are to assess the standard of
the tests provided by a laboratory through interlaboratory
compatibility, promote high-quality testing through educa-
tion and continued improvement, and to recognise the
competence of medical laboratories by their service users,
regulatory authorities, and accreditation bodies.
The widespread introduction of NGS across different
testing strategies has resulted in clinical laboratories ana-
lysing a growing number of targets across a broad range of
conditions. Therefore, since an EQA scheme for NGS
cannot cover every gene variant, it must be delivered as a
technical assessment, and needs to be platform and gene
target agnostic. Critically, it must be able to accommodate
future changes in technology and/or methodology.
A successful NGS EQA creates or has access to a thor-
oughly validated reference truth set against which partici-
pating laboratories can be measured. This requirement
brings challenges in providing large quantities of EQA
material where the validated EQA truth set is unknown to
the participating laboratories. In this paper, we describe the
development of a unique platform and gene target inde-
pendent EQA scheme for NGS, designed to meet current
and future requirements of clinical diagnostic laboratories
testing for germline and somatic variants. We also describe




The EQA scheme was provided annually from 2015 to 2017
as a collaboration between two established providers: the
European Molecular Genetics Quality Network (EMQN)
and the Genomics Quality Assessment (GenQA, previously
known as United Kingdom National External Quality
Assessment Service (UK NEQAS) for Molecular Genetics).
Participation was voluntary and unrestricted; laboratories
enrolled via the EMQN [10] or GenQA [11] websites.
Scheme design
The EQA scheme was designed to be agnostic to the
testing context, platform, and gene target(s); two versions
were provided, germline and somatic as distinct assess-
ments, each one with its own sample. Laboratories were
required to test the EQA sample and generate data fol-
lowing their standard operating procedures. It was not
specified how, or which genes should be tested; single
Fig. 1 Schematic illustration of
the NGS EQA workflow
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genes, gene panels, exomes and whole genomes were
acceptable. Following feedback from the 2015 round,
enhancements were made to the online submission plat-
form so that participants could submit up to three separate
datasets each for the 2016 and 2017 germline and somatic
versions, enabling them to focus on different panels and/
or whole genome sequencing (WGS), or using different
platform/techniques (Fig. 1).
Sample materials
The EQA materials differed depending on the scheme
version. For the germline scheme, each laboratory received
10 µg of genomic DNA (g.DNA) from a lymphoblastoid
cell line (Coriell Cell Repositories, Camden, New Jersey,
USA; 2015—cell line NA00536; 2016—cell line
NA06926; 2017—cell line NA21070) extracted using the
salting out procedure [12]. For the somatic scheme, each
laboratory received identical reference materials derived
from a genetically engineered cell line containing somatic
variants, manufactured by Horizon Discovery Plc, Cam-
bridge, UK [13], or patient-derived materials. In 2015, 5 µg
of DNA extracted using the Promega Maxwell 16 FFPE
plus LEV DNA Purification Kit (Promega cat# AS1135)
from a formalin fixed, paraffin embedded (FFPE) cell line
product (HD200 containing a multiplex of variants in three
different cell line backgrounds—SW48, RKO and
HCT116) was supplied. In 2016, a 10 µm FFPE section
containing a cell line with somatic variants (Horizon Dis-
covery Plc. cell line HD301—KRAS Gene-Specific Multi-
plex Reference Standard) was supplied, along with a 10 µm
FFPE section from the matched normal control i.e. germline
sequence (Horizon Discovery Plc. cell line HD320—
PI3KCA Wild Type Reference Standard). In 2017, 150 ng
of DNA extracted using the Qiagen QiaAmp DNA FFPE kit
from FFPE sections from a breast tumour was supplied
along with 150 ng of DNA extracted using the same method
from matched normal lymph node from the same patient.
Defining the germline variant EQA truth set
Prior to distribution, the 2015 and 2016 germline samples
were independently validated by four different laboratories;
one using WGS (1× Illumina Hi-Seq), and the remaining
three using Whole Exome Sequencing (WES) (2× Illumina
Hi-Seq, 1× ThermoFisher/Life Technologies Proton). A
variant was included in the EQA truth set if called by at
least two validating laboratories due to differences in cov-
erage between captures. In 2017 no predefined truth set was
generated as the only truth set applied was the one obtained
through a process derived from the consensus of the sub-
mitted variants (see below: defining the participant con-
sensus truth sets).
Defining the somatic variant EQA truth set
The 2015 and 2016 somatic EQA samples were indepen-
dently validated by the manufacturer using WES on an
Illumina Hi-Seq platform along with the Droplet Digital
PCR™ (ddPCR) confirmation and quantification of the
allelic frequency of the engineered variants. For the somatic
scheme, the list of ddPCR-confirmed variants reported by
the vendor of the reference sample (Horizon Discovery Plc.)
was used as the EQA truth set.
Assessable regions of the EQA truth sets
The assessable regions determined the genomic regions in
which variants were assessed. Variants near 5′ and 3′ splice
sites often affect splicing, but the effects of these variants on
splicing and disease have not been fully characterised
beyond the two ‘essential’ splice nucleotides flanking each
exon. For the germline scheme, these regions were restric-
ted to the protein-coding exons extended by two base pairs
(bp) (UCSC Table Browser, GRCh37/hg19, https://genome.
ucsc.edu/cgi-bin/hgTables?command= start) into the
intronic regions. Since then further data are available and
there are good reasons to include at least 8 bp in the future
[14]. For the somatic scheme, the assessable regions com-
prised the locations of the known variants in the somatic
variants EQA truth set without extension. In other words,
the truth set was only composed of the collection of features
exactly covering the somatic EQA truth set variants.
Defining the participant consensus truth sets
(germline and somatic)
In 2016 and 2017 a participant consensus truth set was
derived by using the data provided by the participants’
submitted unfiltered (PASS) variants as extracted from the
Variant Calling Files (VCF) [15]. These consensus sets
were established by combining all of the submitted var-
iants that simultaneously satisfied two conditions: (a) the
position of the variant was in the region of interest (ROI)
of at least seven participants, and (b) at least 75% of these
participants agreed on the variant call at the position.
When creating the participant consensus, the submissions
were normalised by splitting multi nucleotide poly-
morphisms (MNPs) into single nucelotide polymorphisms
(SNPs) and left-aligning indels. In 2016 and 2017 the
participant consensus truth set was primarily used in
assessing the participants’ submitted variants. In 2016 the
pre-established EQA truth sets were used as fall-back as
described in the section on concordance analysis. In 2017,
only the consensus truth set was available for participant
assessment. The 2017 participant consensus truth set for
the germline scheme submissions using the GRCh37
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reference genome was checked by evaluating the public
WGS data set for the NA21070 subject available from the
Personal Genomes Project (https://my.pgp-hms.org/
profile/huC30901) against it. The WGS (from 2011)
reached a sensitivity 99.0% and precision of 94.9% for a
total of 21,161 true positives (TP), 1127 false positives
(FP) and 224 false negatives (FN). A random selection of
variants present in the consensus but not the PGP data, and
vice versa (10 of each) were manually curated by a
registered clinical scientist examining aligned reads using
IGV. This showed that the majority of variant calls unique
to the consensus were likely to represent true variants
missing from the PGP data. Variant calls unique to the
PGP data were more complex as some of these calls
appeared to have been missed by participants and some by
PGP. A more in-depth investigation is beyond the scope of
this paper but will be addressed in a follow-up publication.
Assessable regions of the consensus truth sets
In 2016 the assessable region was the same for the con-
sensus truth set as for the EQA truth set for both germline
and somatic. In 2017 the assessable region of the germline
scheme was set to those protein-coding exons in which at
least one consensus variant was included, extended by 2 bp.
For the 2017 somatic scheme, any region further than 1000
bp away from the nearest reported variant was excluded
from the participants’ ROI. This was done to correct for the
large proportion of submissions where the participants had
reported much larger ROI than where they had actually
performed variant calling.
Participant result submissions
Laboratories were required to submit results online to the
EQA providers as a VCF abiding to the VCF version 4.1 or
4.2 standard [15] for their ROI declared in a BED file. The
validity of the VCF and BED file format was automatically
confirmed upon online submission, enabling immediate
feedback to the submitter and amendment of the file by the
participant, if required. In addition, two optional data types
were requested for each submission: the raw data as com-
pressed FASTQ and the alignment as BAM file. In the
2015 scheme, laboratories were also asked to submit a table
of all the genes tested and the transcripts used. This
requirement was amended in the 2016 scheme and labora-
tories were asked to submit a BED file for their ROI instead.
From the 2016 and 2017 schemes it was also possible to
further limit the ROI from the BED file down to named
genes, targets, hot spots, and/or variants through either an
inclusion or an exclusion operation on the BED file. Parti-
cipants were required to complete an online form describing
the sequencing approach(es) employed, the bioinformatics
pipeline(s), and the internally defined quality thresholds
applied.
In order to simplify and triage the data submission pro-
cess, as well as to improve storage and quality control (QC)
aspects of the EQAs, the data collection, storage, and ana-
lysis was contracted out to a commercial bioinformatics
company, Euformatics, (Espoo, Finland) [16].
Concordance analysis
Variant comparison was performed on SNPs and small
indels (<50 bp) submitted by the participant in the inter-
section of the assessable regions (described above) and the
submitted ROI. Before comparison, MNPs were split into
SNPs and indels were normalised by left alignment using
‘bcftools norm’ to ensure that the comparison was correct to
their minimal representation. In 2016, variants were com-
pared against the EQA truth set augmented with the parti-
cipant consensus truth set. Variants were primarily
compared against the EQA truth set, but if there was a
difference between the EQA truth set and the participant
consensus where there was a strong consensus (at least
seven7 participants targeting the position, with at least 75%
of the variant calls in agreement with each other) the par-
ticipant consensus was used as the truth. In 2017 only the
consensus truth set was used for all concordance analysis.
When comparing variants in the germline scheme, it was
required that the called genotype matches. When comparing
variants in the somatic scheme, it was required that the
called alternate allele matches. Each comparison result was
assigned to one of four categories:
● Agree (TP): The submitted variant was identical to the
expected variant in the EQA truth set, or participant
consensus truth set.
● Disagree (FP, FN): The submitted variant was different
to the expected variant in the EQA participant consensus
set, or the EQA truth set.
● Extra (FP): The submitted variant was in a location
where none was expected, neither by the EQA
participant consensus set, or the EQA truth set
● Missing (FN): No submitted variant was found in a
location where one was expected according to the EQA
participant consensus set, or the EQA truth set.
Quality metrics analysis
Participant data for each sample were also analysed in the
2016 and 2017 scheme for a number of different quality
metrics selected based on the EuroGentest and College of
American Pathology (CAP) best practice guidelines [5, 6].
The specific metrics assessed from each file type were: (a)
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FASTQ: Average base quality (Phred quality score), bases
above Q20 and Q30; (b) BAM: Reads uniformity (%), off
target (%), error rate on target, coverage at 20× (%) and at
30× and (in 2017 somatic) 500× (%), insert size average and
standard deviation (for paired-end data only); (c) VCF: Ti/
Tv ratio, quality of calls, SNP and indel counts, Het:Hom
ratio for both SNPs and indels.
Results
Laboratory participation
Participant numbers increased from 182 in 2015, 213 in
2016 to 246 in 2017 for the germline scheme, and from 30
to 59 to 68 for the somatic scheme, respectively. In total,
423 different laboratories from 48 countries participated
over the 3 years with the majority (75.6%) participating
from 11 different countries (Fig. 2).
Consensus sequences
In 2016, the germline scheme truth set contained 22,922
SNPs and 591 indels (maximum size 35 bp, median length
3 bp) and the somatic scheme truth set contained six SNPs
and no indels. In 2017, the participant consensus for
germline scheme submissions using the GRCh37 reference
genome contained 24,344 SNPs and 712 indels (maximum
size 45 bp, median size 3 bp), the participant consensus for
germline scheme submissions using the GRCh38, intro-
duced in 2017, reference genome contained 24,222 SNPs
and 740 indels (maximum size 60 bp, median size 3 bp) and
the participant consensus for somatic scheme submissions
(GRCh37 only) contained 196 SNPs and one indel (deletion
of size 3 bp).
Laboratory practice
Illumina NGS platforms were the most frequently used
(72% in 2015, 73% in 2016, 80% in 2017) followed by
ThermoFisher/Life Technologies Ion Torrent platforms
(25% in 2015, 26% in 2016, 19% in 2017) while a small
number of laboratories used the Roche 454 platform only in
2015 (1.45%). The ThermoFisher/Life Technologies Ion
Torrent platforms were preferred by laboratories doing
somatic variant testing (Fig. 3). The majority of the
sequencing (64%) was bi-directional (paired-end)
sequencing.
Most laboratories (69%) used a commercial kit for DNA
capture or amplification. There was considerable variation
in the kits used, of which 72% were commercially available
and 28% custom designed for the purpose of the laboratory
test (Supplemental data, Table 1).
There was wide variation in the minimum read depth
required to report a variant. In both schemes, 69% of all
participant laboratories confirmed that they would report a
Fig. 2 Country of origin of laboratories participating in the 2015, 2016 and 2017 EQA runs
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diagnostic test result without confirming it by a second,
orthogonal method if it met their minimum read depth and
other quality metric thresholds.
During the 2016 and 2017 EQA runs, over 19,000
unique genes were sequenced. Some laboratories changed
their strategy between the EQA runs to performing WGS
suggesting that this approach may be gaining favour over
WES. Notwithstanding, in all runs the majority (89%) of
laboratories tested small panels of up to 20 genes. BRCA1
and BRCA2 were the most frequently tested genes in the
germline scheme, while other oncogenes such as EGFR,
KRAS and NRAS were the most frequently tested in the
somatic scheme.
Many different bioinformatics approaches including
commercial software and in-house pipelines, for all or part
of an analysis, were employed. The majority of participants
(91%) used in-house bioinformatics pipelines (using self-
made or commercial software tools), with 8% outsourcing
bioinformatics processing to another laboratory/company
(1% did not provide information on their practice).
Laboratories testing smaller panels (<20 genes) were more
inclined to use in-house commercial pipeline tools.
The majority of laboratories employ alignment tools
based on the Burrows−Wheeler Alignment [17] algorithm,
but other aligner strategies were also used (Supplementary
Fig. 1a). For the variant identification the Genome Analysis
Tool Kit [18] tools were most frequently used by the par-
ticipants for variant calling (Supplementary Fig. 1b).
Concordance analysis
The participant laboratory’s variant analysis data were
compared against the relevant truth sets to determine the
sensitivity of their analysis. In 2015 the majority of
laboratories detected the same variants when the same genes
were tested with 74% of laboratories getting >80% sensi-
tivity for variant results calls (not shown). This was
improved in 2016 with 89% of laboratories getting >80%
sensitivity for variant results calls (Fig. 4a). F-scores > 0.80
for germline 2016/2017 was 83%/93% of laboratories, and
for somatic 43%/71% respectively. F-scores > 0.95 for
germline 65%/82% of laboratories, and for somatic 33%/
43% in 2016/2017 respectively.
The effect of the tight selection criteria used to generate
the consensus truth sets (at least seven observations, at least
75% agreement) was that genomic locations that had been
assessed by less than seven laboratories, but still concordant
among those laboratories, did not enter the truth set nor the
assessable region. Such genomic locations were conse-
quently only assessed against the EQA truth set (in 2016),
while in 2017 they were assessed as FPs. Another con-
sequence of the 75% consensus acceptance criteria is that
some genomic locations with seven or more observations
had a majority true variant agreement but were nevertheless
only assessed against the EQA truth set (in 2016) or assessed
as FP (in 2017) because of the 75% agreement not being
reached. A limitation of this approach is that these genomic
locations will likewise generate an FP classification for those
who have found the true variants. As an example, in 2016 a
number of laboratories were outliers in our analyses. Some
laboratories demonstrated low concordance (Fig. 4a) parti-
cularly in the smaller panel size category (lower left section
of Fig. 4a) due to either failing to identify the correct var-
iants, or the reported ROI does not match the one declared
by the participant in the BED file. The latter is demonstrated
by some submissions reporting variants in a subset of their
ROI. Since the concordance is calculated for the declared
ROI as per the BED file, then the sensitivity score was
detrimentally affected from a too wide declared ROI as
compared to the ROI used by the laboratory.
Fig. 3 Different NGS platforms
used by somatic and germline
participants in all three
EQA runs
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Another observation based on the submitted data relates
to the total amount of sequence generated for the variant
calling process. The efficiency of the process can be cal-
culated by considering the amount of raw data generated per
declared variant (Fig. 4b). This will be different for the
germline tests and for the somatic tests, and the expected
allele frequency of the variants will have a bearing on the
number of bases that are required for its identification.
Despite these reservations, and the fact that this does not
provide an estimation of the quality of the performed test,
this nevertheless gives an indication about how much the
costs can vary per called variant. As can be seen in Fig. 4b
for the detection of 50 variants (ca 15 genes), there is an
almost 1000-fold difference between the extreme cases in
terms of total number of bases sequenced. It can also be
seen that those laboratories that perform WES or WGS have
efficiently optimised their assays since there is very little
variation in number of bases sequenced per identified var-
iant (upper right-hand corner of Fig. 4b). A laboratory
should, on a regular basis, use robust validation procedures
with known reference samples to find the optimal trade-off
between cost and quality. Continuous quality control on
informative quality measures can be used to provide an
early alarm of drift in the quality and confidence of the
reported results.
Discussion
EQA is an essential part of the laboratory quality improvement
process and an important component of laboratory accredita-
tion. Traditionally EQA schemes in genetics and molecular
pathology have focussed on targeted testing of single, or small
panels of genes [19–21]. Development of an EQA activity for
NGS has been very challenging due to the complexities of big
data and large variation in the NGS approaches employed. For
example, germline testing requires shallow sequencing depth,
but with the breadth of a large target, e.g. larger gene panels,
clinical exome, whole exome or whole genome. In contrast,
somatic testing requires high read depth to detect variants
present at low allelic frequencies in the samples but focuses on
targeted hot spots providing information for clinical manage-
ment. For germline testing addressing mosaicism, level of
detection below the 50% heterozygous allele frequency may
be needed, which improves with increased read depth. For
somatic testing the clinical utility of detecting low allelic fre-
quency pathogenic variants (often less than 1%) is unknown
(except for liquid biopsies). At low frequency, the signal to
noise ratio weakens and the risk for spurious artefactual
detection increases. The data collated through the EQA
described in this paper confirm these differences in approach
and consequently the value of delivering two versions of this
NGS EQA scheme which were tailored to the specific contexts
of germline and somatic testing.
The design of the germline scheme is suitable for mea-
suring the quality of NGS in a large and diverse group of
participant laboratories. Theoretically, any DNA sample could
be used if sufficient numbers of laboratories participate to
ensure statistical power in the analysis. However, many well-
defined reference samples are also available and could be
used together with the participant consensus data. The power
of these germline-focussed NGS EQAs enables the provision
of unique EQA material for testing, and consequently gen-
erate a new reference genome sequence based on the analysed
participant data. However, for somatic testing this was less
straightforward. We explored several different material
options using artificial reference materials but settled in 2017
on using material derived from a real patient tumour sample
which contained approximately 200 variants thereby
Fig. 4 a Distribution of submissions from the 2016 germline scheme
stratified by ‘goodness’ (correct calls/submitted calls, in %). b The
number of identified SNPs as a function of bases read (from 2016
germline and somatic schemes)
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widening the scope for the participants. Future versions of the
somatic scheme will need to ensure even wider clinical
applicability by including more variants in different genes.
There is a need for reference materials that provide a
highly accurate set of genotypes across a genome to help
measure accurate variant calling. The US National Institute
of Standards and Technology developed the ‘Genome in a
Bottle’ standards [22] to help meet this need and Illumina
developed its Platinum Genomes [23]. Whilst these enable
the accurate measurement of sensitivity and specificity, they
are becoming too familiar to laboratories and thus will no
longer represent a blinded test. Furthermore, as these
reference genomes are being used as the truth set for
algorithm development, there is a significant risk that tools
developed using this information become biased towards
the reference the genomes they were trained/developed on
i.e. assessing the results using the reference sequence used
to develop the protocol. Using the methodology that we
have developed in this EQA, we have demonstrated that it is
possible to generate a new reference genotype from any
sample, including those in publicly available biobanks. We
acknowledge that >70% of laboratories which participated
in our EQA used an Illumina sequencing platform and a
large majority use GATK for variant calling, and therefore
there may be an inherent bias in our process. However, we
consider that this bias is a true reflection of current
laboratory practice and will only change when new NGS
technologies, reference genomes and testing algorithms
become available. Consequently, our EQA may offer
opportunities for participant laboratories to expose their
bioinformatics pipelines to novel reference materials,
thereby improving the quality of their testing process.
Accurate variant calling is dependent on efficiently cap-
turing the targets, good quality sequencing and careful
downstream bioinformatics. Published BPG [5, 6] have
established a large number of different internal quality control
(IQC) metrics which can help laboratories to understand the
factors that affect the quality of NGS, as well as highlight any
problems both with wet-laboratory sample processing and
with dry-laboratory data processing steps. These guidelines
include recommendations for validation or verification, as
well as for systematic and regular quality control on all the
bioinformatics files (FASTQ, BAM, VCF) for every diag-
nostic sample. During the processes of test optimisation and
familiarisation, and validation, control quality metrics
thresholds for all steps including the bioinformatics pipeline
should be established so that they can be systematically
applied to monitor the quality of all diagnostic samples [6].
These metrics, however, do not provide impartial external
assessment. By incorporating a subset of these IQC metrics
into the EQA scheme, a methodology which allows partici-
pating laboratories to benchmark the quality of their data
against their own normal diagnostic samples as well as all
other laboratories using the same platform and/or kit has been
developed and provided. This analysis is helpful for under-
standing the full wet-laboratory and bioinformatics pipeline
and its critical weaknesses in a given NGS strategy and will
further facilitate improvements in NGS testing quality.
The baseline human genome reference sequence, main-
tained by the Genome Reference Consortium [24], is a
consensus assembly from more than one individual used to
provide basic genomic coordinates for each chromosome,
but it does not represent a completed reference. This, in
combination with the fact that many laboratories do not use
a unique and stable sequence reference that is independent
of updates to the reference genome assembly, such as the
Locus Reference Genomic (LRG) [25, 26], means that there
is more variability in reporting of disease-causing variants.
This source of variability was managed by allowing the use
of both GRCh37 and GRCh38 assemblies in 2017; 4% of
the submissions were on GRCh38, half of them from WGS.
Another common source of variability encountered was
differences in the interpretation of data standards [27]. The
FASTQ file format is now well defined having resolved an
early inconsistency with the encoding of quality scores.
Whilst the bioinformatics community owes a great debt to
the 1000 Genomes Project [28] that devised the SAM and
VCF formats and developed samtools, bcftools, VCFtools
and other software tools sets, the specifications for VCFs
cover multiple needs and there might now be a case for a
‘clinical VCF’ building on the gVCF standard now sup-
ported by most tools. The VCF file format, version 4.2 [15]
specifications are both liberal and complex and allow for a
wide variety of different syntaxes for declaring the same
information, creating hurdles for automated computational
analysis, and resulting in different variant callers outputting
quite different codes for the same variants. Multiple
nucleotide variants and indels located very near to each
other pose problems as they can be expressed in different
ways [29]. Normalisation may not handle all edge cases,
and this may lead to errors in the concordance analysis. We
suggest that a stricter definition of how to convey infor-
mation about genotype, about read depth and about allele
frequency should be considered in future updates of the
VCF format specifications. All three parameters are of
cardinal importance in clinical reporting of variants.
During the assessment process we observed that some
commercial software providers apply their own modifica-
tions to the output standards, most notably the removal of
some important quality metrics from the BAM file by the
JSI medical systems software [30] (e.g. mapping quality, off
target % and error rate are considered valuable parameters
by CAP and EuroGentest but absent from the JSI BAM
files). Most other issues concerned the VCF files and a few
issues stand out, particularly as they are of importance in
diagnostic tests. For example, while remaining within the
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liberal boundaries of the VCF format definition, Qiagen
(former CLC Bio) [31] applies a rare syntax for the geno-
type (GT). As described in the results, errors were also
identified in some BED files.
Developing a standard for an EQA for NGS in clinical
diagnostics presents a variety of problems. Firstly, due to
the wide breadth of strategies used by laboratories, it was
not feasible or useful to restrict the EQA to particular
diagnostic testing scenarios since this would significantly
limit the number of participating laboratories. As the aim of
the EQA was to be a technical NGS assessment, then this
was not a suitable approach. Therefore, we aimed for a
truth set covering as many genes as possible. Secondly,
different DNA extraction, capture/amplification, and
library preparation methods, sequencing platforms and
analysis pipelines all have inherent bias with the potential
to produce variation in the observations, making the
development of a truth set difficult. To minimise any bias,
the EQA materials were validated using a variety of NGS
platforms. In 2015 and 2016 this was done on behalf of the
EQA providers, whilst in 2016 and 2017 the participant
results were also used (stemming from multiple different
NGS platforms). In 2016 the two differently derived truth
sets (EQA-derived versus participant-derived) demon-
strated good concordance with an F-score of 0.957. Such
concordance, despite the very strict rules we applied, is
made possible because of the large number of participants
using different measurement technologies. When the truth
set is derived from a participant consensus, a number of
errors may be introduced. In particular, if there is a sys-
tematic error that leads to a large proportion of participants
agreeing on an erroneous variant, it could be incorporated
in to the truth set. In this case, some variants classified as
FNs will not actually be FNs. Conversely, if there is a large
proportion of participants that do not correctly call a var-
iant, it may be left out from the truth set. In this case, some
true variants will be classified as FPs. Further efforts will
be needed to improve the approach to generate a participant
consensus from such a large set of data as is generated by
more than 400 participants.
Finally, this paper has evidenced that a broad range of
software solutions are available to deliver specific parts of
the analytical pipeline. The generation of the raw read data
(FASTQ format) from the sequencer signal (primary ana-
lysis) is systematically handled by the sequencer software.
The secondary analysis covers two critical steps: alignment
of the reads to the reference genome and calling of the
variants from the alignment. The final step (tertiary analysis)
covers variant annotation and classification which can be
performed manually for very small panels of genes but
requires adapted variant interpretation software for larger
gene panels. The observed lack of consensus in bioinfor-
matics tools is understandable, but we consider it worrisome
to observe that many pipelines were relying on tools which
are considered to be outdated and/or no longer supported
(e.g. Illumina MiSeq Reporter™ software v1.0—data from
the 2017 schemes). This may introduce yet another layer of
bias among the types of variants reported. We recommend
that laboratories pay more attention to the version of the
software they are using. We also recommend that labora-
tories ensure they introduce a stringent procedure for internal
validation using internal or commercially available reference
standards, regular verification and continuous quality control
of the bioinformatics pipelines through the quality control of
all samples [32] to be enacted between their EQA rounds.
In conclusion, we have established an EQA scheme for
NGS workflows that is generic, technology and testing con-
text agnostic, and which seamlessly integrates with laboratory
testing pathways and bioinformatics analysis without intro-
ducing the need for new processes or files. This EQA is
therefore suitable for germline as well as somatic variant
testing settings covering the full range from single gene
testing to full genome analysis. Theoretically, it could be
extended to any discipline-specific EQA scheme (e.g.,
microbiology, virology, microbiome, etc.) where the primary
focus is establishing interlaboratory comparison of the NGS
testing process. The EQA results presented indicate that the
laboratories participating in the 2015, 2016 and 2017
assessments are providing an ever-improving high-quality
NGS service. However, there are still multiple challenges
facing EQA delivery in this field; assessing large genomic
rearrangements (structural variants, SV), copy number chan-
ges, (copy number variants, CNV), dealing with pseudogenes,
GC rich and repetitive sequence regions, selecting perfor-
mance criteria and applying quality thresholds, perhaps dif-
ferentially over different parts of the genome, comparing
similar NGS approaches between cohorts with meaningful
numbers, sample sourcing and dealing with evolving and
nonstandardised data formats. External pressure applied on
the commercial manufacturers of the NGS systems and other
interested parties is required to further harmonise and stan-
dardise these data types. This will result in better data quality,
and facilitate improved data sharing among laboratories,
which eventually will aid in delivering higher standards of
NGS testing in patient clinical test pathways.
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